Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720544 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL223965 | 0.98 | SMN1; SMN2 (0.38) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL28099249 | 0.93 | SMN1; SMN2 (0.35) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5792847 | 0.91 | — | — | |
| SCHEMBL222917 | 0.91 | — | — | |
| Ethylene Glycol SCHEMBL28161259 | 0.87 | MEN1 (0.47) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL16615781 | 0.85 | DNM1 (0.36) | LMNATSHRDNM1 | |
| SCHEMBL16615645 | 0.85 | DNM1 (0.36) | LMNATSHRDNM1 | |
| Ethylene Glycol SCHEMBL27905296 | 0.84 | MEN1 (0.43) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| Ethylene Glycol SCHEMBL8210958 | 0.82 | TSHR (0.44) | LMNAMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180126731-A1 | INK DISCHARGE DEVICE AND INK DISCHARGE METHOD | RICOH COMPANY, LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20150353518-A1 | CATALYST AND CATALYTIC PROCESS FOR THE ETHERIFICATION/REDUCTION OF FURFURYL DERIVATIVES TO TETRAHYDROFURFURYL ETHERS | UNIVERSITAT POLITECNICA DE VALENCIA (ES) | 2015-12-10 | — | — | US | disclosed |
| EP-2913328-A1 | CATALYST AND CATALYTIC PROCESS FOR THE ETHERIFICATION/REDUCTION OF FURFURYL DERIVATIVES TO TETRAHYDROFURFURYL ETHERS | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2015-09-02 | — | — | EP | disclosed |
| US-9109129-B2 | Inkjet ink, inkjet recording method, and inkjet recording apparatus | RICOH COMPANY, LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| US-9062217-B2 | Liquid composition, recording method, and recorded matter | RICOH COMPANY, LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9033484-B2 | Inkjet treatment liquid and inkjet recording apparatus | RICOH COMPANY, LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9011588-B2 | Inkjet treatment liquid and image forming method using treatment liquid | RICOH COMPANY, LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| US-8980408-B2 | Liquid composition, recording method, and recorded matter | RICOH COMPANY, LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8820875-B2 | Image forming method and inkjet recording device using the same | RICOH COMPANY, LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140240391-A1 | INKJET INK, INKJET RECORDING METHOD, AND INKJET RECORDING APPARATUS | RICOH COMPANY, LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20120128949-A1 | IMAGE FORMING METHOD, AND IMAGE FORMED MATTER | RICOH COMPANY, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20110318543-A1 | LIQUID COMPOSITION, RECORDING METHOD, AND RECORDED MATTER | RICOH COMPANY, LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6737544-B1 | HEATING ABOVE MELTING POINT | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-18 | — | — | US | disclosed |
| US-6639070-B1 | 4-substituted 1,3,4-oxadiazines; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-28 | — | — | US | disclosed |
| EP-1187819-B1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6525000-B1 | N-aminoureas are reacted with formaldehyde to give methyleneimino ureas, cyclizing these to give tetrahydro-4H-1,3,4-oxa(or thia)diazines, and cyclizing the fused triazoles using phosgene; herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| EP-1095045-B1 | METHOD FOR PRODUCING ANELLATED TRIAZOLES AND NEW ANELLATED TRIAZOLES AND THEIR USE | BASF AG (DE) | 2003-01-15 | — | — | EP | disclosed |
| EP-0835248-B1 | 1-AMINO-3-BENZYLURACILS | BASF AG (DE) | 2001-02-21 | — | — | EP | disclosed |
| US-6150303-A | Substituted 3-phenylisoxazolines | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | LMNA 3553/4885MEN1 4291/4885KMT2A 1521/4885 |
| US-20150353518-A1 | CATALYST AND CATALYTIC PROCESS FOR THE ETHERIFICATION/REDUCTION OF FURFURYL DERIVATIVES TO TETRAHYDROFURFURYL ETHERS | ADH1A, ADH1C, ADH5 | LMNA 3240/4885MEN1 1678/4885KMT2A 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.